Logo del repository
  1. Home
 
Opzioni

Development of Eosinophilic Granulomatosis With Polyangiitis Despite Anti–Interleukin-5 Receptor Therapy: The First Case of Bilateral Central Retinal Artery Occlusion During Benralizumab Treatment

Treppo E.
•
Finocchio L.
•
Fazzi B.
altro
Quartuccio L.
2025
  • journal article

Periodico
ACR OPEN RHEUMATOLOGY
Abstract
Here, we describe a rare presentation of eosinophilic granulomatosis with polyangiitis (EGPA) under benralizumab therapy manifesting as bilateral central retinal artery occlusion (CRAO). The patient, a 61-year-old man with chronic eosinophilic rhinosinusitis and severe asthma, experienced sudden bilateral visual loss and transient amaurosis. Ophthalmologic evaluations, including a fundus examination and optical coherence tomography, confirmed CRAO, and laboratory test results revealed elevated markers of inflammation and positive antimyeloperoxidase antibodies in the context of normal eosinophil counts. Intensive immunosuppressive therapy led to resolution of systemic inflammation, although significant visual impairment persisted. These findings underscore the potential limitations of anti–interleukin-5 receptor therapy in preventing vasculitic complications in EGPA.
DOI
10.1002/acr2.70073
WOS
WOS:001517440300010
Archivio
https://hdl.handle.net/11390/1309024
info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-105007159349
https://ricerca.unityfvg.it/handle/11390/1309024
Diritti
open access
google-scholar
Get Involved!
  • Source Code
  • Documentation
  • Slack Channel
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your nstitution's web identity.

Need professional help?

The original creators of DSpace-CRIS at 4Science can take your project to the next level, get in touch!

Realizzato con Software DSpace-CRIS - Estensione mantenuta e ottimizzata da 4Science

  • Impostazioni dei cookie
  • Informativa sulla privacy
  • Accordo con l'utente finale
  • Invia il tuo Feedback